
中国如何通过AI协作重塑全球医药创新格局?
地缘政治不确定性和监管壁垒上升,正在推动药物研发从传统的单打独斗模式转向跨境合作。中国生物医药行业正借助AI和跨国企业的深度协作,加快临床管线研发,并降低全球研发成本。
Eric Tse is the Chief Executive Officer of Sino Biopharmaceutical Limited, one of Asia's most prominent life-science companies and the only Chinese-headquartered firm ranked seven consecutive years in Pharmaceutical Executive?s Global Top 50. With degrees from the Wharton School and Tsinghua University, he combines analytical rigor with a global perspective. Under his leadership, Sino Biopharm has accelerated innovation pipelines and expanded its therapies to reach 100 million+ patients worldwide. Alongside his corporate work, Eric is a globally engaged youth leader, with roles across the Global Shapers Community, the All-China Youth Federation, and multiple forums advancing cross-cultural dialogue and emerging-leader development.
地缘政治不确定性和监管壁垒上升,正在推动药物研发从传统的单打独斗模式转向跨境合作。中国生物医药行业正借助AI和跨国企业的深度协作,加快临床管线研发,并降低全球研发成本。
Rising geopolitical uncertainties and regulatory barriers are forcing a shift from traditional solo global pharma development towards cross-border partnerships
